"Short Course" Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1, 2010, Pages 70-77

  Gasparetto, Cristina ^a   Gockerman, Jon P ^a   Diehl, Louis F ^a   de Castro, Carlos M ^a   Moore, Joseph O ^a   Long, Gwynn D ^a   Horwitz, Mitchell E ^a   Keogh, George ^b   Chute, John P ^a   Sullivan, Keith M ^a   Neuwirth, Rachel ^c   Davis, Patricia H ^a   Sutton, Linda M ^a   Anderson, Russell D ^a   Chao, Nelson J ^a   Rizzieri, David ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Charleston Hematology Oncology Associates   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Autologous transplantation; Induction therapy; Multiple myeloma

Indexed keywords

ACICLOVIR; ANTIEMETIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOPOIETIC GROWTH FACTOR; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CD34 SELECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HERPES ZOSTER; HUMAN; INFECTION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; SHORT COURSE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PYRAZINES; STATISTICS AS TOPIC; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 72649101695     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.08.017     Document Type: Article

References (28)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. Blood 111 (2008) 2962-2972
2. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
3. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
4. Bladé J., Rosinol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106 (2005) 3755-3759
5. van de Velde H., Liu X., Chen G., et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92 (2007) 1399-1406
6. Cavo M., Tacchetti P., Patriarca F., et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood 112 Suppl (2008) Abstract 158
7. Harousseau J.L., Mathiot C., Attal M., et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial. J Clin Oncol 26 Suppl (2008) 455s
8. Sonneveld P., van der Holt B., Schmidt-Wolf I.G.H., et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Blood 112 Suppl (2008) Abstract 653
9. Richardson P.G., Mitsiades C., Schlossman R., et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 8 (2008) 1053-1072
10. Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9 (2003) 1136-1144
11. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
12. Jagannath S., Richardson P.G., Barlogie B., et al. SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91 (2006) 929-934
13. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99 (2002) 4525-4530
14. Berenson J.R., Yang H.H., Vescio R.A., et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol 87 (2008) 623-631
15. Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 108 (2006) 2165-2172
16. Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 93 (2008) 560-565
17. Boccadoro M., Palumbo A., Bringhen S., et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 87 (2002) 846-850
18. De la Rubia J., Blade J., Lahuerta J.J., et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica 91 (2006) 621-627
19. Richardson P.G., Briemberg H., Jagannath S., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24 (2006) 3113-3120
20. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473
21. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
22. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 (2008) 906-917
23. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
24. Facon T., Mary J.Y., Pegourie B., et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107 (2006) 1292-1298
25. Hernandez J.M., Garcia-Sanz R., Golvano E., et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 127 (2004) 159-164
26. San Miguel J.F., Schlag R., Khuageva N.K., et al. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma. Blood 112 Suppl (2008) Abstract 650
27. Mateos M.-V., Oriol A., Martinez J., et al. Bortezomib (Velcade)-melphalan-prednisone (VMP) versus Velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for Velcade: an alkylating or an immunomodulator agent?. Blood 112 Suppl (2008) Abstract 651
28. Palumbo A., Schlag R., Khuageva N., et al. Prolonged therapy with bortezomib plus melphalan-prednisone (VMP) results in improved quality and duration of response in the phase III VISTA study in previously untreated multiple myeloma (MM). Haematologica 93 Suppl (2008) 83